Help provided by CD4 + T cells to B cells is essential for the formation of germinal centers (GCs) and the generation of long-lived high-affinity antibodies. Follicular helper T cells (T FH cells) have been defined as a unique CD4 + T cell subset that provides such help to B cells [1] [2] [3] [4] . T FH cells are characterized by the expression of molecules that facilitate functional interactions with B cells, including the chemokine receptor CXCR5, the cytokine interleukin 21 (IL-21) and the costimulatory molecules PD-1 and ICOS [1] [2] [3] [4] [5] [6] [7] [8] . T FH cells also distinctively have high expression of the transcription factor Bcl-6, which has been demonstrated to be a central regulator of T FH cell differentiation [9] [10] [11] .
Help provided by CD4 + T cells to B cells is essential for the formation of germinal centers (GCs) and the generation of long-lived high-affinity antibodies. Follicular helper T cells (T FH cells) have been defined as a unique CD4 + T cell subset that provides such help to B cells [1] [2] [3] [4] . T FH cells are characterized by the expression of molecules that facilitate functional interactions with B cells, including the chemokine receptor CXCR5, the cytokine interleukin 21 (IL-21) and the costimulatory molecules PD-1 and ICOS [1] [2] [3] [4] [5] [6] [7] [8] . T FH cells also distinctively have high expression of the transcription factor Bcl-6, which has been demonstrated to be a central regulator of T FH cell differentiation [9] [10] [11] .
T FH cell differentiation has been proposed to be a multistage, multifactorial process 4 . Studies have shown that this differentiation involves interactions of CD4 + T cells with various types of antigenpresenting cells, such as dendritic cells (DCs) and B cells 8, [12] [13] [14] [15] . The presentation of antigen by DCs is necessary and sufficient to initiate the T FH cell-differentiation program consisting of early induction of the expression of CXCR5, Bcl-6 and ICOS [14] [15] [16] . The interaction of ICOS with its ligand ICOSL is critical in 'instructing' T FH cell differentiation; in the absence of ICOS or in the presence of blocking antibodies to ICOSL, T FH cell differentiation is substantially impaired 8, 14 . After the DC priming stage, further T FH cell differentiation involves a B cell-dependent stage 9, [14] [15] [16] [17] in which signaling via ICOS is required for both the maintenance of Bcl-6 expression in T FH cells and the follicular relocation of T FH cells into GCs 14, 16, 18 . In the absence of B cells, DC-initiated T FH cell responses are aborted 14, 15 .
In addition to antigen-presenting cells and costimulation via ICOS, the cytokine milieu has important roles in T FH cell differentiation 7, 8, [19] [20] [21] [22] [23] . IL-6 and IL-21 (which engage the pathways of the signal transducers STAT1 and STAT3) and IL-2 (which engages the STAT5 pathway) have been shown to favor T FH cell differentiation and limit it, respectively 7, 8, [19] [20] [21] . IL-21 also acts directly on B cells at various stages of GC B cell responses [24] [25] [26] . At the transcriptional level, Bcl-6 and its antagonist Blimp-1 have central roles in T FH cell differentiation 9 . Several other transcription factors (Batf, Irf4, c-Maf and Ascl2) are also important for T FH cell development [27] [28] [29] [30] [31] . Despite all these findings, the molecular mechanisms that underlie T FH cell differentiation, particularly initial T FH cell development, have remained unclear.
The forkhead box ('Fox') proteins constitute a large family of transcription factors with diverse functions 32, 33 . Foxp1, a member of the 'Foxp' subfamily, is expressed in many tissues and has four isoforms (Foxp1A, Foxp1B, Foxp1C and Foxp1D) 34 . In cells of the T lineage, Foxp1 has important roles in both the generation of quiescent naive T cells and the maintenance of naive T cell quiescence in the periphery 35, 36 .
Here we report that in a T cell-dependent immune response, Foxp1 was a rate-limiting and critical negative regulator of T FH cell differentiation. We found that in addition to using its constitutive Foxp1A isoform, Foxp1 also used a Foxp1D isoform induced by stimulation via the T cell antigen receptor (TCR) to efficiently block initial T FH cell development and that the negative regulation of T FH cell differentiation by Foxp1A and Foxp1D was dose dependent. Mechanistically, 6 6 8 VOLUME 15 NUMBER 7 JULY 2014 nature immunology A r t i c l e s we found that Foxp1 directly and negatively regulated IL-21 and that Foxp1 dampened the expression of ICOS and its downstream signaling, which resulted in partial resistance of Foxp1-deficient CD4 + T cells to blockade of ICOSL during T FH cell development. The negative regulation of T FH cell differentiation by Foxp1 also showed profound dominance, such that even in the absence of B cells, Foxp1-deficient CD4 + T cells differentiated into T FH cells at high frequencies with sustained Bcl-6 expression. Our findings demonstrate that the two Foxp1 isoforms provide a 'double-check' mechanism for fundamental regulation of T FH cell differentiation and humoral responses.
RESULTS

TCR stimulation transiently induces Foxp1D expression
To study how Foxp1 regulates the responses of CD4 + T cells to challenge with antigen, we first examined Foxp1 expression patterns during the activation of CD4 + T cells. We found that in wild-type naive CD4 + T cells, upon stimulation in vitro with antibody to the invariant signaling protein CD3 (anti-CD3) and antibody to the coreceptor CD28 (anti-CD28), expression of constitutive full-length Foxp1A was constant; conversely, among the other three shorter isoforms, expression of only Foxp1D was induced (Fig. 1a) . Consistent with those immunoblot analysis results, intracellular staining revealed increased total Foxp1 protein following activation (Fig. 1b) , reflective of the induction of Foxp1D expression. The TCR-induced expression of Foxp1D decreased when the TCR stimulation was withdrawn (Fig. 1c) , which suggested that sustained Foxp1D expression was dependent on the duration of TCR stimulation. Nevertheless, once T cells were activated (as indicated by expression of the activation marker CD44), both low and high doses of TCR stimulation induced similar expression of Foxp1D protein (Supplementary Fig. 1a) .
To demonstrate that the induction of Foxp1D expression in activated CD4 + T cells also occurred in vivo, we transferred naive OT-II T cells (which have transgenic expression of an ovalbumin (OVA)-specific TCR) into Ly5.1 + C57BL/6 recipient mice, followed by immunization of the recipients with OVA conjugated to 4-hydroxy-3-nitrophenylacetyl (NP-OVA) in alum. At 2 d after immunization, intracellular staining showed that the total amount of Foxp1 in proliferating donor OT-II T cells had increased, and by day 3, it started to decrease (Fig. 1d) . Immunoblot analysis revealed that Foxp1D expression was indeed induced in donor OT-II T cells at day 3, with almost no change in Foxp1A expression (Fig. 1e) . By days 4-5, Foxp1 in donor OT-II T cells decreased to amounts equivalent to those of naive T cells (Supplementary Fig. 1b) . Thus, during the initial days of an in vivo immune response, Foxp1D expression was transiently induced in CD4 + T cells by antigen stimulation.
Foxp1 negatively regulates T FH cell differentiation
We crossed mice that undergo conditional deletion of loxP-flanked Foxp1 alleles (Foxp1 f/f ) mediated by Cre recombinase expressed from the gene encoding a tamoxifen-sensitive estrogen receptor variant (Cre-ERT2) and express yellow fluorescent protein (YFP) from the ubiquitously expressed Rosa26 locus (Foxp1 f/f Cre-ERT2 + Rosa YFP mice) 36 with OT-II mice to generate OT-II Foxp1 f/f Cre-ERT2 + Rosa YFP mice. We sorted CD44 lo CD62L hi CD25 -YFP + naive Foxp1-deficient OT-II (OT-II Foxp1-cKO) T cells or naive Foxp1-sufficient (Foxp1-wild-type) OT-II (OT-II Foxp1-WT) T cells from tamoxifen-treated OT-II Foxp1 f/f Cre-ERT2 + Rosa YFP mice or from control OT-II Foxp1 f/f Rosa YFP mice (or OT-II Foxp1 +/+ Cre-ERT2 + Rosa YFP mice), respectively. We then transferred the sorted cells into SMARTA mice (which have transgenic expression of a TCR specific for the lymphocytic choriomeningitis virus epitope of glycoprotein amino acids 66-77), followed by immunization of the recipient mice with NP-OVA in alum. We used SMARTA mice as recipients to reduce the competition between transferred donor OT-II T cells and host T cells in response to challenge with NP-OVA 13 . In the subsequent 2 weeks after immunization, OT-II Foxp1-cKO T cells and OT-II Foxp1-WT T cells responded with similar kinetics and magnitudes of population expansion and contraction (Fig. 2a) . However, the OT-II Foxp1-cKO T cell population contained a much higher frequency and number of CXCR5 hi PD1 hi T FH cells, with a correspondingly lower frequency and number of non-T FH cells, than that of the OT-II Foxp1-WT T cell population (Fig. 2a,b) . On the basis of staining for the marker GL7 and CXCR5 (ref. 37) , OT-II Foxp1-cKO T cell population also included a higher frequency of GC T FH cells (Fig. 2c) . OT-II Foxp1-cKO and OT-II Foxp1-WT T FH cells were phenotypically indistinguishable (CD44 hi CD62L lo ICOS hi BTLA hi CD200 hi ; Fig. 2d ) and expressed similar amounts of Bcl-6 protein (Fig. 2e) . Experiments with Ly5.1 + C57BL/6 mice as recipients resulted in a similarly increased frequency of T FH cells among Foxp1-deficient OT-II T cells but a lower magnitude of response than that observed with SMARTA mice ( Supplementary  Fig. 2a-c and data not shown). These results suggested that deletion of Foxp1 in naive CD4 + T cells led to the 'preferential' development of T FH cells and GC T FH cells at the expense of non-T FH cells. Thus, Foxp1 had a negative regulatory role in T FH cell development. 
A r t i c l e s
Studies have shown that Foxp3 + follicular regulatory T cells have an important role in suppressing T FH cell development 38, 39 . We stained cells for Foxp3 and found that neither OT-II Foxp1-WT T cells nor OT-II Foxp1-cKO T cells generated any Foxp3 + OT-II follicular regulatory T cells in SMARTA recipient mice (Supplementary Fig. 3a ). There was also no difference between the two groups of SMARTA recipient mice in their regulatory T cell populations ( Supplementary  Fig. 3a) . Finally, we transferred OT-II Foxp1-WT T cells and OT-II Foxp1-cKO T cells together into the same recipient mouse and found that the Foxp1-deficient OT-II T cell population still contained a substantially higher frequency of T FH cells (Supplementary Fig. 3b ), which suggested that the effect of Foxp1 on T FH differentiation was cell intrinsic. As for the role of Foxp1 in the differentiation of other subsets of CD4 + T cells, we found that while the loss of Foxp1 did not seem to alter differentiation of the T H 1 or T H 17 subset of helper T cells in vitro, it might have slightly favored the differentiation of T H 2 cells (Supplementary Fig. 4 ).
Foxp1-deficient T FH cells lead to enhanced GC responses
Consistent with the enhanced T FH cell response noted above, both the frequency and number of GC B cells in the recipient mice that received OT-II Foxp1-cKO T cells were higher than those in mice that received OT-II Foxp1-WT T cells (Fig. 3a) . Histological analysis of spleen sections 6 d after immunization showed that the mice that received OT-II Foxp1-cKO T cells had an increased size and frequency of GCs (Fig. 3b) . By day 6 after immunization with antigen, more OT-II Foxp1-cKO T cells than OT-II Foxp1-WT T cells had already localized to the follicles and GCs (Fig. 3b) , which suggested that Foxp1-deficient T FH cells acted anatomically and functionally like T FH cells.
By day 7 after immunization, although the number of antibodysecreting cells that produced NP-specific immunoglobulin M (IgM) was similar in both groups of recipient mice (Fig. 3c) , the number of antibody-secreting cells producing NP-specific total IgG and IgG1 in mice that received OT-II Foxp1-cKO T cells was almost tenfold greater than that in their counterparts that received OT-II Foxp1-WT T cells (Fig. 3c) . NP-specific IgG antibodies of both low affinity (antibodies to a NP 25 -BSA (NP conjugated to bovine serum albumin (BSA) at a molecular ratio of 25:1)) and high affinity (antibodies to NP 4 -BSA (NP conjugated to BSA at a molecular ratio of 4:1)) were also produced at much higher titers in recipients of OT-II Foxp1-cKO T cells (Fig. 3d) . Thus, the enhanced T FH cell responses of Foxp1-deficient CD4 + T cells correlated with greatly increased GC responses and the production of antibodies of both low affinity and high affinity.
TCR-induced Foxp1D blocks initial T FH differentiation
Given the implications of the differences in isoform expression following stimulation of the TCR (Fig. 1a,b,d ,e), we investigated the individual roles of Foxp1A and Foxp1D in T FH cell differentiation. We generated mice with conditional transgenic expression of the specific isoforms Foxp1A and Foxp1D through the use of a Rosa26 locus-knock-in approach ('Foxp1a Tg/Tg mice' and 'Foxp1d Tg/Tg mice' , respectively; Supplementary Fig. 5a,b) . We crossed those mice with mice that express Cre recombinase from the T cell-specific Cd4 promoter (Cd4-Cre) to generate Foxp1a Tg/Tg Cd4-Cre mice and Foxp1d Tg/Tg Cd4-Cre mice, respectively. Naive T cells from both mouse lines developed in normal numbers with a normal phenotype and expressed green fluorescent protein (GFP) as a marker ( Supplementary Fig. 5c,d ). In addition to using the model antigen OVA, we also extended the studies and used a model of infection with influenza virus. We infected Foxp1a Tg/Tg Cd4-Cre and Foxp1d Tg/Tg Cd4-Cre mice with influenza virus strain A/Puerto Rico/8/34 (PR8) and found that both transgenes potently suppressed the generation of T FH cells and subsequent GC B cell responses ( Supplementary Fig. 6a-d) . We also observed suppression of T FH cell development by the transgene encoding Foxp1D in naive OT-II T cells from OT-II Foxp1d Tg/Tg Cd4-Cre mice in the OVA model ( Supplementary Fig. 7a ). The suppression of T FH cell development by Foxp1D was specific rather than being a general suppression of CD4 + T cell responses, as the overall magnitude of the CD4 + T cell responses was similar for wild-type OT-II T cells and OT-II T cells with transgenic expression of Foxp1D when they were transferred together into the same Ly5.1 + C57BL/6 recipient mice, followed by immunization of the recipients with NP-OVA in alum (Supplementary Fig. 7b ). Together our results suggested that Foxp1, including both constitutively expressed 
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Foxp1A and TCR-induced Foxp1D, had a negative role in T FH cell development.
In the OT-II OVA model, T FH cells began to develop around day 3 (ref. 40) (Fig. 2a) , the time at which Foxp1D expression began to decrease from its peak at day 2 ( Fig. 1d) . To achieve Foxp1D-specific deletion and address whether Foxp1D induced by stimulation of the TCR has a role in blocking initial T FH cell development, we generated OT-II Foxp1a Tg/+ Foxp1 f/f Cd4-Cre (OT-II Foxp1D-KO) mice. This resulted in deletion of all endogenous Foxp1 with maintenance of T cell-specific expression of the transgene encoding Foxp1A (Fig. 4a,b) . In recipient mice given OT-II Foxp1-WT T cells or OT-II Foxp1D-KO T cells, at 3 d after immunization with NP-OVA in alum, only a small proportion of OT-II Foxp1-WT T cells differentiated into CXCR5 hi PD1 hi T FH cells (Fig. 4c) , whereas almost 40% of the donor OT-II Foxp1D-KO T cells developed into T FH cells (Fig. 4c) . This occurred even though the abundance of transgenically expressed Foxp1A protein in OT-II Foxp1D-KO T cells was higher than the abundance of endogenous Foxp1A in OT-II Foxp1-WT T cells (Fig. 4a) . By day 7, the frequency of OT-II Foxp1D-KO T FH cells was still higher than that of OT-II Foxp1-WT control cells (Fig. 4c) . These results demonstrated that during the early stages of a T cell-dependent response, Foxp1D induced by antigen stimulation was particularly critical in blocking initial T FH cell differentiation.
Sum of Foxp1 proteins serves as a rate-limiting factor
Knowing that both Foxp1A and Foxp1D inhibited T FH cell differentiation ( Supplementary Fig. 6a,c) , we next sought to determine whether the 'dose' of Foxp1 protein was critical for T FH cell development. The amount of Foxp1A in naive T cells from mice with heterozygous Foxp1 expression is lower than that in wild-type T cells 36 . Here we found that both Foxp1A and Foxp1D had lower expression in activated CD4 + T cells from such heterozygous mice than in their wild-type counterparts (Fig. 4a,b) . We transferred naive OT-II T cells from tamoxifen-treated OT-II Foxp1 f/f Rosa YFP (OT-II Foxp1-WT) mice, OT-II Foxp1 f/+ Cre-ERT2 + Rosa YFP (OT-II Foxp1-Het) mice or OT-II Foxp1 f/f Cre-ERT2 + Rosa YFP (OT-II Foxp1-cKO) mice into SMARTA mice and immunized the recipients with NP-OVA in alum. At either day 3 or days 7-8 after immunization, the frequency of OT-II Foxp1-Het T FH cells was intermediate between that of OT-II Foxp1-WT T FH cells and that of OT-II Foxp1-cKO T FH cells (Fig. 4d) . These results demonstrated dose-dependent regulation of T FH cell differentiation by Foxp1 and suggested that the sum of total Foxp1 served as a rate-limiting factor for T FH cell development. 
Foxp1-deficient T FH cells are true T FH cells
To initially address the mechanism underlying the substantial effect of Foxp1 on T FH cell development, we analyzed global gene expression in T FH cells generated in vivo. We identified a group of 118 highly T FH cellspecific genes by combining gene-expression data obtained with OT-II Foxp1-WT T FH cells and three publically available data sets of T FH cell expression (GEO accession codes GSE24574, GSE16697 and GSE40068; Fig. 5a and Supplementary Table 1) . We found high concordance in the expression profiles of wild-type and Foxp1-deficient CXCR5 hi PD1 hi T FH cells (Pearson r 2 = 0.90), and most of the 118 T FH cell-specific genes and genes encoding some additional markers had similar expression in the two groups of T FH cells (Fig. 5a and Supplementary Table 1) . Thus, phenotypically, anatomically and functionally, Foxp1-deficient T FH cells were very similar to wild-type T FH cells.
In addition to assessing the 118 T FH cell-specific genes, we also assessed mRNA encoding a group of key molecules known to be critical for T FH cell differentiation. We compared the abundance of these mRNAs in wild-type and Foxp1-deficient CD4 + T cells activated in vitro under conditions that promote the differentiation of T FH cell-like cells 4 . Consistent with the results obtained for T FH cells ex vivo (Fig. 5a) , all the genes analyzed by reverse transcription followed by quantitative PCR had similar expression in the two groups of T FH cell-like cells in vitro (Supplementary Fig. 8a ).
Foxp1 directly and negatively regulates IL-21
A few of the 118 T FH cell-specific genes had higher expression in Foxp1-deficient T FH cells than in wild-type T FH cells, and one of these was the gene encoding IL-21 ( Fig. 5a and Supplementary Table 1) . Indeed, we did find that a greater proportion of ex vivo OT-II Foxp1-cKO T cells than OT-II Foxp1-WT T cells produced IL-21 (Fig. 5b) , which suggested that Foxp1 may have negatively regulated IL-21. The T H 1 cell-inducing cytokine IL-12 has been shown to induce IL-21 production 22, 23 . Thus, we examined IL-21 production under T H 1-polarizing culture conditions in vitro. We found that a higher frequency of Foxp1-deficient T H 1 cells than wild-type cells produced IL-21 at the level of both protein and mRNA (Fig. 5c,d) . Notably, under the same T H 1-polarizing culture conditions, the transgene encoding Foxp1D specifically suppressed the production of IL-21 but not the production of interferon-γ (Supplementary Fig. 8b ), which suggested that IL-21 may have been directly regulated by Foxp1. Bioinformatics analysis identified one highly conserved forkhead-binding consensus site in the promoter region of the locus encoding IL-21 across species (Fig. 5e) . Chromatin-immunoprecipitation analysis of Foxp1 in wild-type T H 1 cells showed that Foxp1 bound specifically to the Il21 promoter region (Fig. 5e) . Together these in vivo and in vitro results suggested that Foxp1 negatively and directly regulated IL-21.
Partial resistance to blockade of ICOSL Foxp1 did not seem to regulate ICOS expression directly ( Fig. 5a and Supplementary Fig. 8a) . However, by examining the OT-II T cells at the early time points after T cell activation, we found that ICOS expression was higher in Foxp1-cKO T cells than in Foxp1-WT T cells both in vitro and in vivo (Fig. 6a,b and Supplementary Table 2 ). This suggested that the Foxp1 pathway indirectly dampened the initial cell-surface abundance of ICOS during T cell activation.
It has been reported that ICOS-mediated signaling via phosphatidylinositol-3-OH kinase is critical for the generation of T FH cells 41 . Activation of signaling via phosphatidylinositol-3-OH kinase and the kinase Akt induces the phosphorylation of Foxo1 and leads to the A r t i c l e s degradation of Foxo1 protein 33 . Therefore, we assessed the activation of Foxo1 in OT-II T cells in recipient mice given transfer of OT-II Foxp1-WT or OT-II Foxp1-cKO T cells, followed by immunization of the recipients with NP-OVA in alum and analysis 3 d later.
In donor OT-II T cells at day 3 ex vivo, we found that the amount of total Foxo1 was slightly but significantly lower in Foxp1-deficient cells than in wild-type control cells ( Fig. 6c and Supplementary Table 2) , which suggested that, consistent with the enhanced induction of ICOS, downstream signaling via ICOS in Foxp1-deficient OT-II T cells was also more activated. The negative regulation of ICOS expression and signaling via ICOS by Foxp1 led us to hypothesize that the T FH differentiation of Foxp1-deficient T cells would be resistant to blockade of ICOSL. In recipient mice given transfer of OT-II Foxp1-WT or OT-II Foxp1-cKO T cells and treated with antibodies to ICOSL, we found that the antibodies blocked 70-80% of the T FH differentiation of OT-II Foxp1-WT T cells; however, such antibodies blocked only about 30% of the T FH differentiation of OT-II Foxp1-cKO T cells (Fig. 6d) , and OT-II Foxp1-cKO T FH cells still expressed Bcl-6 (Fig. 6e) . Collectively, these results suggested that Foxp1-deficient CD4 + T cells were partially resistant to the blockade of ICOSL during T FH differentiation.
Profound effect of Foxp1 on T FH cell differentiation
After the initial DC priming stage and during the T cell-B cell interaction stage, ICOS signaling has been shown to have critical roles in maintaining T FH cell differentiation 8, 14 . The partial resistance of the T FH differentiation of Foxp1-deficient CD4 + T cells to the blockade of ICOSL led us to investigate whether Foxp1-deficient CD4 + T cells would still differentiate into T FH cells in the absence of B cells. We found that, as reported 14 , in B cell-deficient µMT recipient mice given OT-II Foxp1-WT T cells or OT-II Foxp1-cKO T cells and then challenged with NP-OVA in alum, the T FH development of OT-II Foxp1-WT T cells was aborted (Fig. 7a) . Strikingly, compared with OT-II Foxp1-WT control cells, OT-II Foxp1-cKO T cells not only elicited enhanced T FH cell responses in µMT recipient mice (Fig. 7b) but also exhibited T FH cell frequencies even higher than those of OT-II Foxp1-WT T cells in B cell-intact recipient mice (Fig. 7a) . The finding that the total number of OT-II Foxp1-cKO T FH cells was lower in µMT recipient mice than in B cell-intact recipient mice (Figs. 2a and 7b ) might have resulted from the much lower number of total donor OT-II T cells (Foxp1-cKO as well as Foxp1-WT) at the early stage (day 3) of the response after transfer (Supplementary Fig. 9 ). The decrease in the OT-II Foxp1-cKO T FH cell response seemed to be sharper in µMT recipient mice than in B cell-intact recipient mice (Figs. 2a  and 7b) , which suggested that B cells may be important for the survival of T FH cells. Nevertheless, given that the T FH cell response of OT-II Foxp1-WT T cells in µMT recipient mice was aborted (Fig. 7a,b) , the induced OT-II Foxp1-cKO T FH cell response in µMT recipient mice was notable. In µMT recipient mice, OT-II Foxp1-cKO T FH cells exhibited a conventional T FH cell phenotype, with 10-20% even able to convert into GL7 hi CXCR5 hi GC T FH cells (Supplementary Fig. 10a,b) . The frequency of IL-21-producing cells was also higher among OT-II Foxp1-cKO T cells than among OT-II Foxp1-WT T cells (Supplementary Fig. 10c ). At later time points, when the responses were diminishing, OT-II Foxp1-cKO T FH cells continued to express Bcl-6 in the absence of B cells (Fig. 7c) . Thus, even in the absence of B cells, Foxp1-deficient T cells generated substantial T FH cell responses. The substantial effect of Foxp1 on T FH cell differentiation in the absence of B cells led us to compare the T FH development of Foxp1-deficient T cells with overexpression of Bcl-6. As reported for cells in vivo 9, 18, 29 , overexpression of Bcl-6 in OT-II Foxp1-WT T cells enhanced their T FH development ( Fig. 7d and Supplementary  Fig. 11a-c) . However, unexpectedly, the frequency of OT-II T FH cells generated in the absence of Foxp1 was much higher than that of OT-II Foxp1-WT T cells that overexpressed Bcl-6 ( Fig. 7d and  Supplementary Fig. 11c) . We obtained similar results with either Ly5.1 + C57BL/6 mice or SMARTA mice as the recipients (data not shown). Retroviral overexpression of Foxp1A (or Foxp1D) 'rescued' the abnormally enhanced T FH differentiation of OT-II Foxp1-cKO T cells (Fig. 7d, Supplementary Fig. 11c and data not shown).
In addition to assessing this in OT-II T cells, we also investigated the function of Foxp1 in the T FH differentiation of SMARTA T cells. We introduced Cre expression into SMARTA Foxp1 f/f T cells in vitro by retroviral infection after T cells were activated and then transferred the infected T cells into the Ly5.1 + C57BL/6 recipient mice. We found that the Foxp1-deficient SMARTA T cell population also contained a higher frequency of T FH cells after immunization of recipient mice with the lymphocytic choriomeningitis virus peptide gp61 conjugated to keyhole limpet hemocyanin (gp61-KLH) (Fig. 7e) . Among SMARTA T cells, the frequency of T FH cells generated in the absence of Foxp1 was almost as high as that among T cells overexpressing Bcl-6 (Fig. 7e) . Thus, in both the OT-II model system and the SMARTA model system, our results showed that Foxp1 exhibited profound dominance in regulating T FH cell differentiation.
DISCUSSION
During the initial days of an immune response, how T FH cells arise from activated CD4 + T cells is still poorly understood 3, 4 . Our study has established that Foxp1, through the use of two isoforms as a 'double-check' mechanism, is a rate-limiting and critical negative regulator of T FH cell differentiation. Our results have demonstrated important roles for the constitutive Foxp1A isoform and TCR-induced Foxp1D isoform in the control of the kinetics and magnitude of T FH cell development, which in turn greatly affects the subsequent GC and antibody responses.
Foxp1 has an essential role in maintaining the quiescence of naive T cells, partly by negatively regulating the pathway of the kinases MEK and Erk 36 . Signaling via MEK-Erk has a critical role in inducing ICOS expression by TCR stimulation: constitutively active MEK2 amplifies transcription of Icos, and a site in the promoter of Icos that is sensitive to Erk signaling has also been identified 42 . The initially enhanced induction of ICOS expression in Foxp1-deficient CD4 + T cells both in vitro and in vivo at early stages of T cell activation was probably due to the lack of the negative regulation of Foxp1 on MEK-Erk signaling. The enhanced expression of ICOS on Foxp1-deficient T cells, presumably through the interaction of ICOS with ICOSL-expressing DCs during the initial priming stage 14 , would lead to enhanced ICOS signaling, reflected by increased activation and degradation of Foxo1 protein, as we observed in ex vivo OT-II Foxp1-cKO T cells. It is plausible that in a T cell-dependent immune response, in the absence of Foxp1, higher ICOS expression and stronger ICOS signaling would allow more CD4 + T cells to differentiate into T FH cells. Meanwhile, the partial resistance of Foxp1-deficient CD4 + T cells to the blockade of ICOSL also suggested that mechanisms other than ICOS signaling contributed to the 'preferential' T FH differentiation of Foxp1-deficient CD4 + T cells and would provide a rationale for how Foxp1-deficient CD4 + T cells still differentiated into T FH cells in the absence of B cells. The Foxp1-mediated initial restraint of the expression of ICOS, a costimulator for T cell activation, could also be viewed as part of the Foxp1 function in controlling T cell quiescence. Thus, the function of the Foxp1 pathway in T cell quiescence seems to be linked to its role in T FH cell differentiation.
Although antigen dose has been shown to be important for T FH cell responses 17, 43 , studies have suggested that the effector pattern of CD4 + T cells is also influenced by both the density and the dwell time of complexes of peptide and major histocompatibility complex class II rather than by TCR affinity alone 44 . OT-II and SMARTA model systems have been shown to generate different effector-cell patterns 44 . 7, 8, 25 . Extensive studies have shown that IL-21 acts directly on B cells and affects many aspects of GC B cell responses, including proliferation, survival and affinity selection, as well as differentiation into memory and plasma cells [24] [25] [26] . In our study, we found that IL-21 was a direct target of Foxp1 and that Foxp1 negatively regulated IL-21 in CD4 + T cells. Whereas it is very likely that the increased IL-21 production in Foxp1-deficient CD4 + T cells helped to generate the enhanced T FH cell responses and subsequent GC B cell responses we observed in our study, to what extent and whether Foxp1 may regulate some other T FH cell functions in helping B cell responses remains to be explored.
In our study, we found that the regulation of T FH cell differentiation by Foxp1 was dose dependent. The sum of Foxp1A and Foxp1D together served as a rate-limiting factor for the generation of T FH cells. In T FH cell differentiation, Foxp1A and 1D functioned in a very similar manner in that they both dampened such differentiation. The only domain that Foxp1D lacks is a polyglutamine-repeat domain, whose function has been characterized as the mediation of proteinprotein interactions 45 . At present, little is known about partners that interact with Foxp1A or Foxp1D in their transcriptional complexes. Nevertheless, it is notable that Foxp1D, which peaked around day 2 in the OT-II OVA model, efficiently blocked T FH cell differentiation during the initial stage of the immune response. Such a 'gatekeeper' function for Foxp1D would be intrinsic to the immune response, as Foxp1D is induced mainly by TCR stimulation. Furthermore, our results showed that the 'preferential' T FH differentiation of Foxp1-deficient CD4 + T cells occurred at the expense of non-T FH cells. Thus, whereas this regulatory step is clearly critical for T cell-dependent GC responses, these results also indicate that Foxp1 may have roles in aspects of an immune response that depend on CD4 + non-T FH helper T cells as well.
In summary, our study has defined an important role for Foxp1 in T FH cell differentiation. Through the use of two isoforms as a 'double-check' mechanism, Foxp1 is a rate-limiting and critical negative regulator of T FH cell differentiation. The unique attributes of Foxp1 in CD4 + T cells may provide a useful pathway for manipulating humoral responses in vaccine development or the treatment of autoimmune disorders.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. GEO: microarray data, GSE50725. Microarray. For sample preparation and hybridization, total RNA from purified CXCR5 hi PD1 hi T FH or CXCR5 − PD1 − non-T FH cells was isolated with TRIzol reagent according to the manufacturer's recommendations (Invitrogen). RNA quality was assesse with a Bioanalyzer (Agilent). Only samples with RNAintegrity numbers of ≥9.5 were used for further studies. Equal amounts (400 ng) of total RNA was amplified as recommended by Illumina and was hybridized to the Illumina MouseWG 6v2 mouse whole-genome bead arrays.
For data preprocessing, Illumina GenomeStudio software was used to export expression values and the calculated detection P values for each probe of each sample. Signal-intensity data were log 2 transformed and quantile-normalized. Only genes with a significant detection P value (P < 0.05) in at least one of six samples were considered. The data were submitted to the GEO database.
For the external data set, preprocessed external sets of T FH cell-related data with accession numbers GSE24574, GSE16697 and GSE40068 were downloaded from the GEO database 9, 16, 47 .
For analysis of differences in expression, the SAM ('significance analysis of microarrays') method 48 was used to find genes expressed differently in the T FH cell class (two replicates) and non-T FH cell class (one replicate) with the 'One class' option for data from T FH cells, with expression values for non-T FH sample subtracted from those values. Genes expressed differently in the data sets GSE24574, GSE16697 and GSE40068 were identified by the two-tailed Student's t-test, and the false-discovery rate was estimated with a published procedure 49 . Genes with a false-discovery rate of <5% were considered significant.
To identify overlapping of genes encoding T FH cell markers in our Illumina data and in the publicly available Affymetrix data in GSE24574, GSE16697 and GSE40068, we used accession codes of the Entrez databases (National Center for Biotechnology Information) associated with each Illumina or Affymetrix probe as identified by software of the DAVID bioinformatics database (Database for Annotation, Visualization and Integrated Discovery) 50 . For Entrez accession codes with multiple associated probes, only the probe with the highest expression was considered.
For the identification of T FH cell markers, a set of genes with significant expression (false-discovery rate, <5%) in GSE24574, GSE16697 and GSE40068 and nominal P value of <0.01 in wild-type samples were 'called' as T FH cell markers; these were used to estimate similarity between OT-II Foxp1-WT cells and OT-II Foxp1-cKO T FH cells.
Enzyme-linked immunospot assay. ELISPOT plates (Millipore) were coated overnight at 4 °C with 10 µg/ml NP 25 -BSA (Biosearch Technologies) or BSA in PBS, then nonspecific binding was blocked with DMEM medium containing 10% FBS. Serial dilutions of splenocytes were cultured in the coated plates at 37 °C in 5% CO2. After incubation overnight, plates were washed with PBS containing 0.05% Tween 20 and were incubated with alkaline phosphataseconjugated anti-IgM (1020-04; SouthernBiotech), anti-IgG (1030-04; SouthernBiotech) and anti-IgG1 (115-055-205; Jackson ImmunoResearch Laboratiories). Antibody spots were developed with the NBT/BCIP substrate (Santa Cruz). The frequency of antibody-secreting cells was determined with an ImmunoSpot Reader (CTL) and ImmunoSpot satellite software (CTL).
Enzyme-linked immunosorbent assay. ELISA plates (Costa) were coated overnight at 4 °C with 10 µg/ml NP 4 -BSA (Biosearch Technologies, Inc.) or NP 25 -BSA in 0.1 M carbonate buffer (pH 9.0). Nonspecific binding in the coated plates was blocked with 3% BSA in PBS and plates containing serial dilutions of serum were incubated for 2 h at room temperature, followed by incubation with alkaline phosphatase-coupled anti-IgG (identified above). Alkaline phosphatase activity was visualized with p-nitrophenyl phosphate substrate (Sigma-Aldrich) and the absorbance at 405 nm was determined with an ELISA reader (Molecular Devices). Titers represent the highest serum dilution with a value of ≥0.1 above background for absorbance at 405 nm.
Histology. These procedures were done as described 40 . 0.1 × 10 6 purified naive OT-II Foxp1-WT or OT-II Foxp1-cKO T cells were transferred together with 0.5 × 10 6 B1-8 hi B cells into Ly5.1 + SMARTA mice, followed by immunization of the recipient mice with NP-OVA in alum. At day 6 after immunization, spleens were fixed for 1 h at 4 °C in 4% paraformaldehyde and 10% sucrose in PBS, then were incubated overnight in 30% sucrose before being embedded in optimum cutting temperature compound and cryosectioned. Samples were then fixed for 10 min at −20 °C in acetone, nonspecific binding was blocked with a Streptavidin/Biotin Blocking Kit (Vector Labs) and samples were stained in the following three steps: first, with purified rat anti-mouse (mAID-2; eBioscience) plus biotin-anti-CD45.2 (104; BD Biosciences); second, with Alexa Fluor 555-conjugated goat polyclonal anti-rat (A-21434; Invitrogen) plus Alexa Fluor 488-streptavidin (Invitrogen); and third, with Alexa Fluor npg 647-conjugated rat antibody to mouse IgD (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) BioLegend) . All samples were incubated in a solution of 5% BSA, 10% normal mouse serum and 0.1% Triton X-114 in PBS. Mounted sections were imaged on a Zeiss 700 confocal microscope with a 5× objective with a numerical aperture of 0.25 and a 20× objective with a numerical aperture of 0.8. Table 2 ) were used for calculation of P values, except for calculation of P values for microarray analyses, in which SAM test was also used.
Statistics. Two-tailed Student's t-tests and paired t-tests (Supplementary
